Several studies demonstrated that ABCG2 is a major transporter for the efflux of sorafenib [14, 53] and sorafenib-resistant HCC cells also expressed higher levels of ABCG2 [54] but till now there is no study explaining the effect of inhibition Nrf2 on reduction sorafenib’s efflux and resistance. This evidence concerns the gene ABCG2 and hepatocellular carcinoma.